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Background: Coronaviruses pose a serious threat to global health as evidenced by Severe Acute Respiratory Syn-
drome (SARS), Middle East Respiratory Syndrome (MERS), and COVID-19. SARS Coronavirus (SARS-CoV), MERS
Coronavirus (MERS-CoV), and the novel coronavirus, previously dubbed 2019-nCoV, and now officially
named SARS-CoV-2, are the causative agents of the SARS, MERS, and COVID-19 disease outbreaks, respectively.
Safe vaccines that rapidly induce potent and long-lasting virus-specific immune responses against these infectious
agents are urgently needed. The coronavirus spike (S) protein, a characteristic structural component of the viral
envelope, is considered a key target for vaccines for the prevention of coronavirus infection.
Methods: We first generated codon optimized MERS-S1 subunit vaccines fused with a foldon trimerization
domain to mimic the native viral structure. In variant constructs, we engineered immune stimulants (RS09 or fla-
gellin, as TLR4 or TLR5 agonists, respectively) into this trimeric design. We comprehensively tested the pre-clini-
cal immunogenicity of MERS-CoV vaccines in mice when delivered subcutaneously by traditional needle
injection, or intracutaneously by dissolvingmicroneedle arrays (MNAs) by evaluating virus specific IgG antibodies
in the serum of vaccinated mice by ELISA and using virus neutralization assays. Driven by the urgent need for
COVID-19 vaccines, we utilized this strategy to rapidly develop MNA SARS-CoV-2 subunit vaccines and tested
their pre-clinical immunogenicity in vivo by exploiting our substantial experience with MNAMERS-CoV vaccines.
Findings: Here we describe the development of MNA delivered MERS-CoV vaccines and their pre-clinical immuno-
genicity. Specifically, MNA delivered MERS-S1 subunit vaccines elicited strong and long-lasting antigen-specific
antibody responses. Building on our ongoing efforts to develop MERS-CoV vaccines, promising immunogenicity of
MNA-deliveredMERS-CoV vaccines, and our experience with MNA fabrication and delivery, including clinical trials,
we rapidly designed and produced clinically-translatable MNA SARS-CoV-2 subunit vaccines within 4 weeks of the
identification of the SARS-CoV-2 S1 sequence. Most importantly, these MNA delivered SARS-CoV-2 S1 subunit vac-
cines elicited potent antigen-specific antibody responses that were evident beginning 2weeks after immunization.
Interpretation: MNA delivery of coronaviruses-S1 subunit vaccines is a promising immunization strategy
against coronavirus infection. Progressive scientific and technological efforts enable quicker responses to
emerging pandemics. Our ongoing efforts to develop MNA-MERS-S1 subunit vaccines enabled us to rapidly
design and produce MNA SARS-CoV-2 subunit vaccines capable of inducing potent virus-specific antibody
responses. Collectively, our results support the clinical development of MNA delivered recombinant protein
subunit vaccines against SARS, MERS, COVID-19, and other emerging infectious diseases.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license.
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Research in context
Evidence before this study
Coronavirus is an emerging pathogen with exponentially
increasing significance due to the high case fatality rate, the
large distribution of reservoir, and the lack of medical counter-
measures. The public health emergencies caused by Coronavi-
ruses, including SARS-CoV, MERS-CoV, and now SARS-CoV-2,
clearly demonstrate the urgency to evaluate candidate vaccines
to combat these outbreaks. Continuous research efforts from
previous epidemics contribute to the efforts of investigators to
quickly develop safe vaccines against these emerging infec-
tions; however, the recent COVID-19 pandemic highlights an
important continuing need for the rapid design, production,
testing, and clinical translation of candidate vaccines.
Added value of this study
These studies demonstrate the rapid development and immu-
nogenicity of novel microneedle array (MNA) delivered recom-
binant coronavirus (SARS-CoV-2) vaccines. MNA delivered
MERS-S1 subunit vaccines induced potent and long-lasting
antigen antigen-specific immune responses. Notably, MNA
delivery of these vaccines generated significantly stronger
immune responses than those administered by traditional sub-
cutaneous needle injection, indicating the improved immuno-
genicity by skin-targeted delivery. These efforts with MNA
MERS-S1 subunit vaccines enabled the rapid design and pro-
duction of MNA SARS-CoV-2 vaccines, capable of eliciting
potent virus-specific antibody responses that were evident as
early as 2 weeks after immunization. Rapid design and produc-
tion of MNA-embedded SARS-CoV-2-S1 subunit vaccines using
clinically applicable MNA fabrication methods supports the
development of MNA delivered recombinant coronavirus vac-
cines for clinical vaccine applications. Collectively, our studies
support the clinical development of MNA protein subunit vac-
cines for COVID-19 and other emerging infectious diseases.
Implications of the available evidence
MNA delivery of coronaviruses-S1 subunit vaccines is a promising
immunization strategy against MERS-CoV and SARS-CoV-2 infec-
tion and can be adapted for other subunit vaccines against a broad
range of infectious diseases. The recent advances in recombinant
DNA technology and vaccine delivery strategies enable quick
design, production, and testing of vaccines against emerging
infections. We plan to evaluate these SARS-CoV-2 vaccines for
other important predictors of vaccine efficacy in humans, includ-
ing the induction of neutralizing antibodies and for their ability to
prevent infection in animal challenge models, when these assays
and preclinical models become available. Thus far, our studies
suggest that it may now be possible to produce clinical grade vac-
cines against novel pathogens for human testing and subsequent
global distribution in time to significantly impact the spread of
disease.
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On December 31, 2019, Chinese authorities in Wuhan announced
a cluster of pneumonia cases of unknown etiology, most of which
included patients who reported exposure to Wuhan’s Huanan Sea-
food wholesale market. Emergence of another pathogenic zoonoticPlease cite this article as: E. Kim et al., Microneedle array delivere
translational development, EBioMedicine (2020), https://doi.org/10.1016HCoV was suspected, and on January 9, 2020, the Chinese Center for
Diseases Control reported that a novel coronavirus was the causative
agent. Shortly thereafter the genomic sequences of several isolates
became publicly available. On February 10, 2020, the WHO named
the disease, caused by the new coronavirus, COVID-19, and the new
virus was named severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Genomic analyses indicated that SARS-CoV-2 shares
genomic similarities with SARS-CoV within the receptor-binding
motif that directly contacts the human receptor ACE2. This has
important implications for vaccine design and for predicting pan-
demic potential. Human-to-human transmission of SARS-CoV-2 has
now been established, and the situation with SARS-CoV-2 is evolving
rapidly with the numbers of verified cases growing into the thou-
sands. Accordingly, The World Health Organization (WHO) has
declared COVID-19 a global pandemic.
Another recently emerged coronavirus, the Middle East Respiratory
Syndrome Coronavirus (MERS-CoV) was first isolated in 2012 in Saudi
Arabia [1]. As of January 31st, 2020 the World Health Organization
(WHO) has been notified of 2,513 laboratory-confirmed cases of infec-
tion with MERS-CoV that include 864 related deaths with a fatality
rate of 34.4% [2]. Cases have arisen in 27 countries globally, including a
severe outbreak in the Republic of Korea in 2015 [3,4]. MERS-CoV is
still endemic in the Middle East, most particularly in Saudi Arabia,
where more than 80% of cases have occurred. No efficacious drugs or
vaccines are currently approved for human use [2,5]. The WHO
included MERS-CoV on the list of priority blueprint diseases for which
there is an urgent need for accelerated research and development of a
safe and efficacious vaccine [5,6].
For both these coronaviruses, the spike (S) protein is crucial for
viral transmission and infection, and determines the tropism of the
virus and host cell entry. SARS-CoV-2 binds the ACE2 receptor as
MERS-S binds to the cellular receptor dipeptidyl peptidase 4 (DPP4)
via the receptor-binding domain (RBD) in the N-terminal surface sub-
unit (S1), and then employs its C-terminal transmembrane subunit
(S2) to fuse with the host cell membrane. [7-11] Due to this vital
functional property and established antigenicity, the S protein is an
important target for vaccine development. Our previous studies have
shown that adenoviral vaccine candidates expressing SARS-CoV-S1
and MERS-S1 subunits induced more efficacious antibody-mediated
neutralizing activity than full-length S1, suggesting the subunit
immunogen as an ideal vaccine candidate [12]. The native S proteins
exist as a trimeric form on the surface of the virus. However, when its
ectodomain or S1 is expressed as a recombinant protein in eukaryotic
systems, the protein exists predominantly in a monomeric form
[13,14]. Here, to make trimeric recombinant codon optimized subunit
proteins mimicking the native viral structures, we have fused the
MERS-CoV-S1 and SARS-CoV-2-S1 segments to a 27-amino acid
sequence called the foldon domain, which is a natural trimerization
domain derived from the C terminus of bacteriophage T4 fibritin
[15,16]. Inclusion of a foldon trimerization domain promotes a tri-
meric structure and has been shown to increase the immunogenicity
of several viral antigens including Influenza virus hemagglutinin,
HIV-1 glycoprotein, and SARS-CoV S1/S-ectodomain, supporting the
importance of mimicking native viral trimeric structures [14,17,18].
Further, recent work has shown that a recombinant trimeric recep-
tor-binding domain (RBD) of MERS-CoV, made by fusing RBD with
foldon domain (RBD-Fd), elicits potent RBD-specific neutralizing anti-
bodies and protects hDPP4 transgenic mice from viral infection [19].
To potentially improve the immunogenicity of these vaccines, we
also constructed S1 subunits with integrated Toll-like receptor (TLR)
agonist sequences, specifically RS09 and flagellin C. RS09 is a syn-
thetic form of an LPS mimic 7-mer peptide, which binds to TLR4 and
induces nuclear localization of the transcription factor NF-kB, result-
ing in transcription of inflammatory cytokines and secretion of che-
mokines [20]. Flagellin is a highly conserved natural bacterial ligand
that binds to TLR5 to activate TLR5 expressing dendritic cells,d recombinant coronavirus vaccines: Immunogenicity and rapid
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immunogenicity in several vaccine models [2123].
The skin is an ideal target for immunization. It contains a rich popu-
lation of antigen presenting and immune accessory cells capable of
inducing a proinflammatory microenvironment favoring the induction
of potent and durable adaptive immunity [24,25]. Of several emerging
skin-targeted drug delivery methods, dissolving MNAs have emerged as
a minimally-invasive intracutaneous approach [2628]. MNAs used
here are developed from mechanically strong water-soluble polymers
to physically breach the outermost layer of skin (stratum corneum) and
then rapidly dissolve in the underlying viable epidermis and dermis to
deliver cargos to skin microenvironments [27,29].
Importantly, MNA delivery results in high concentrations of vaccine
components in the local skin microenvironment, thereby contributing
to a dose-sparing effect that could decrease the required vaccine doses
for efficacious immunization and substantially reduce both cost and
toxicity [27,30-32]. Although the stability of each vaccine candidate in
MNAs needs to be validated at different temperatures for varying stor-
age periods, the available literature indicates that MNA-embedded
vaccines have the potential to remain stable for an extended period of
time without expensive “cold chain” requirements [33,34]. Further,
previous animal and clinical studies suggest that MNAs could provide
a safe and well-tolerated delivery platform for efficacious immuniza-
tion strategies [3539].
Here, we demonstrate the rapid development of MNA SARS-CoV-2
S1 subunit vaccines and their promising immunogenicity in mice devel-
oped using our evolving experience with MERS-CoV vaccines and
MNAs. First, we evaluate the immunogenicity of trimeric form of MERS-
S1 subunit vaccines delivered subcutaneously by traditional needle
injection, or intracutaneously by MNAs. Driven by the promising immu-
nogenicity of MNA-MERS-S1 vaccines and the urgent need to respond
to the recent coronavirus pandemic (COVID-19), we rapidly (within
4 weeks of the identification of the SARS-CoV-2 S1 sequence) designed
and produced MNA SARS-CoV-2 S1 vaccines and tested their immuno-
genicity in mice. We describe the rapid development of MNA embedded
SARS-CoV-2-S1 subunit vaccines using clinically-applicable MNA pro-
duction methods by relying on our experience with clinical trials utiliz-
ing MNA delivery (ClinicalTrials.gov Identifier: NCT02192021). Taken
together, our results support the development of MNA delivered recom-
binant coronavirus vaccines for clinical applications.
2. Materials and methods
2.1. Construction of adenoviral vectors and plasmids
The codon-optimized gene encoding MERS-S1 (amino acids 1 to
725 of full-length MERS S, according to the GeneBank JX869059)
lacking stop codon flanked with SalI & BamHI was amplified by PCR
from pAd/MERS-S1 12 and was used to replace the ZIKV-E in in pAd/
ZIKV-Efl 40 at SalI & BamHI sites fused with BamH I-linked T4 fibritin
foldon trimerization domain (f), Tobacco Etch Virus Protease (Tp),
and six histidine tag (6H), generating plasmid pAd/MERS-S1f. For
the construction of pAd/MERS-S1fRS09 or pAd/MERS-S1ffliC, BamH
I-fTp6H-Not I of pAd/MERS-S1f was replaced with codon optimized
BamH I-f-RS09(APPHALS)-Tp6H-Not I or BamH I-f-fliC (GenBank
ACY88831)-Tp6H-Not I. Subsequently, replication-defective human
adenovirus serotype 5, designated as Ad5.MERS-S1f, Ad5.MERS-
S1fRS09, and Ad5.MERS-S1ffliC, were made by loxP homologous
recombination and purified and stored as described previously
[4143].
For the construction of pmax/SARS-CoV-2-S1, the codon-optimized
gene encoding SARS-CoV-2-S1 amino acids 1 to 661 of full-length
from BetaCoV/Wuhan/IPBCAMS-WH-05/2020 (GISAID accession id.
EPI_ISL_403928) lacking stop codon flanked with HindIII-SalI &
BamHI-6H-NotI was synthesized (GenScript) and generated by sub-
cloning the codon-optimized SARS-CoV-2-S1 gene into pmaxCloningPlease cite this article as: E. Kim et al., Microneedle array delivere
translational development, EBioMedicine (2020), https://doi.org/10.1016(Lonza), at HindIII/NotI sites. For the construction of pmax/SARS-CoV-
2-S1fRS09, BamH I-6H-Not I of pmax/SARS-CoV-2-S1 was replaced
with codon optimized BamH I-f-RS09(APPHALS)-Tp6H-Not I.
2.2. Purification of recombinant proteins
The recombinant proteins named rMERS-S1f, rMERS-S1fRS09, and
rMERS-S1ffliC were expressed in Human Embryonic Kidney (HEK)
293 cells infected with Ad5.MERS-S1f, Ad5.MERS-S1fRS09, and Ad5.
MERS-S1ffliC, respectively, and purified by His60 Ni Superflow Resin
(Clontech) under native conditions from the supernatant as described
previously [40]. Briefly, the purified recombinant proteins were
treated with AcTEV protease (Life Technology) followed by affinity
chromatography on a His60 Ni Superflow Resin to remove six-histi-
dine tags and poly-histidine tagged protease from the cleavage reac-
tion. The cleaved native recombinant proteins were collected from
the flow-through fraction. The eluted solution was concentrated and
desalted with phosphate buffered saline (PBS) in an Amicon Ultra
centrifugal filter devices (Millipore).
For expression of recombinant proteins, rSARS-CoV-2-S1 and
rSARS-CoV-2-S1fRS09, 293HEK cells were transfected by electropora-
tion (Celetrix). Briefly, 293HEK cells were counted and suspended with
plasmids in the electroporation buffer at 5 £ 107 cells, 200mg/ml. The
mixture containing cells and plasmids was transferred into 1ml Cele-
trix electroporation tube with 25 mm distance between the electrodes,
and immediately subjected to electroporation under 930V and 30ms,
and then incubated for 72 hrs at 37°C in a humidified atmosphere
with 5% CO2. The recombinant proteins, rSARS-CoV-2-S1 and rSARS-
CoV-2-S1fRS09, were purified by His60 Ni Superflow Resin (Clontech)
under native conditions from the supernatant as described previously
[40]. The concentrations of the purified recombinant proteins were
determined by the Bradford assay using bovine serum albumin (BSA)
as a protein standard.
2.3. SDS-PAGE and Western blot
To evaluate the recombinant adenoviruses, A549 cells were trans-
duced with ten multiplicity of infection (MOI) of Ad5.MERS-S1f, Ad5.
MERS-S1fRS09, and Ad5.MERS-S1ffliC. At six hours after infection,
cells were washed three times with PBS, and added with serum-free
media, and incubated for 48 h. The supernatant of A549 infected with
adenoviruses were subjected to sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) and Western blot. Briefly, after
the supernatants were boiled in Laemmli sample buffer containing
2% SDS, or native sample buffer, with or without beta-mercaptoetha-
nol (b-ME), the proteins were separated by Tris-Glycine SDS-PAGE
gels and then transferred to polyvinylidene fluoride (PVDF) mem-
brane. After blocking for 1h at room temperature with 5% non-fat
milk in PBST, anti-6xHis monoclonal antibody (1:50000) (Invitrogen)
were added and incubated overnight with at 4 °C as primary anti-
body, and horseradish peroxidase (HRP)-conjugated goat anti-mouse
IgG (1:10000) (SantaCruz) was added and incubated at RT for 2 h as
secondary antibody. After washing three times with PBS, the signals
were visualized using ECL Western blot substrate reagents and Amer-
sham Hyperfilm (GE Healthcare).
2.4. Fabrication of dissolvable microneedle arrays
Dissolvable microneedle arrays (MNAs) incorporating the protein
MERS-S1f, MERS-S1fRS09, MERS-S1ffliC, SARS-CoV-2-S1, or SARS-
CoV-2-S1fRS09) were fabricated from carboxymethyl cellulose (CMC,
90 kDa MW) at room temperature (22°C) using our previously
described three-stage MNA manufacturing strategy [29,32]. Briefly,
the production molds were prepared by casting Polydimethylsiloxane
(PDMS, SYLGARD 184) elastomer onto themicromachinedMNAmas-
ter molds that include 100 obelisk-shaped microneedles in a 10 £ 10
d recombinant coronavirus vaccines: Immunogenicity and rapid
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to be 750 mm, 225 mm, and 30°, respectively. Next, CMC-based MNA-
rMERS-S1f, MNA-rMERS-S1fRS09, MNA-rMERS-S1ffliC, MNA-rSARS-
CoV-2-S1, or MNA-rSARS-CoV-2-S1fRS09 vaccines were produced
through a two-step spin-drying technique. First, 20 ml of purified pro-
tein was dispensed onto each MNA production mold and centrifuged
for 1 min at 2500 g to fill the microneedle cavities. Subsequently, the
excess solution was removed, and the residual protein solution was
spin-dried into the tip of the microneedle cavities of the mold by cen-
trifugation at 2500 g for 30 min. The tip-loaded protein in the produc-
tion molds was overlayered with 75 mg of CMC hydrogel (20% w/w) to
form the mechanically strong microneedles and the backing layer of
the MNAs. The molds loaded with the CMC-hydrogel were then centri-
fuged for 3 h at 2500 g to obtain final dissolvable MNA vaccines. The
theoretical loading of each MNA-rMERS-S1f, MNA-rMERS-S1fRS09,
MNA-rMERS-S1ffliC, SARS-CoV-2-S1, or SARS-CoV-2-S1fRS09 was 25
mg, 25mg, 40 mg, 20 mg, or 20 mg proteins, respectively. The geomet-
ric integrity of the fabricated MNAs was confirmed through optical
stereomicroscopy imaging before the experiments. Importantly, this
MNA design and fabrication strategy has also been used for MNAs uti-
lized in our ongoing Phase 1 clinical trials (ClinicalTrials.gov Identifier:
NCT02192021). In line with our efforts toward clinical production of
MNA SARS-CoV-2 subunit vaccines, we gamma irradiation (25 kGy)
sterilized a small group of these MNA SARS-CoV-2 subunit vaccines to
determine clinically relevant sterilizing conditions and any effect on
immunogenicity.
2.5. Animals and Immunization
BABL/c mice (five animals per group) were inoculated subcutane-
ously with 25 mg of MERS-S1f only, 25 mg of MERS-S1f plus 20 mg of
MPLA (monophosphoryl lipid A; TLR-4 agonist), 25 mg of MERS-
S1fRS09, and 40 mg of MERS-S1ffliC or PBS as a negative control and
1011vp of Ad5.MERS-S1 as a positive control. It is noted that MPLA was
added in a single control group at similar doses as used previously to
establish a positive control for the adjuvanted subunit vaccines [44].
The MNA rMERS-S1f, rMERS-S1fRS09, or rMERS-S1ffliC vaccines were
applied to the abdomen of anesthetized mice and removed after
10 min. Two weeks after the primary immunization, mice were
boosted intranasally (i.n.) or intracutaneously (MNAs) with the same
dose of the corresponding immunogens.
For SARS-CoV-2 study, C57BL/6 female mice (five animals per
group) were inoculated intracutaneously with MNAs loaded with of
SARS-CoV-2-S1 or SARS-CoV-2-S1fRS09 protein, or PBS as a negative
control. At two weeks after the primary immunization, mice were sim-
ilarly boosted with the same dose of the corresponding immunogens.
To preliminarily evaluate the effects of sterilizing gamma irradiation
on MNA-SARS-CoV-2 vaccines, 2 mice per group were irradiated using
clinical sterilizing conditions. Mice were bled from the saphenous vein
at week 0, 1, 2, 3, and 4, and serum samples were evaluated for SARS-
CoV-2-S1 antibody by enzyme-linked immunosorbent assay (ELISA).
Mice were maintained under specific pathogen-free conditions at
the University of Pittsburgh, and all experiments with mice were con-
ducted in accordance with animal use guidelines and protocols
approved by the University of Pittsburgh’s Institutional Animal Care
and Use (IACUC) Committee.
2.6. FACS analysis
Two weeks after the prime immunization, pooled sera were
obtained from all mice and screened for MERS-S-specific antibodies
using fluorescence-activated cell sorter (FACS) analysis of Human
Embryonic Kidney (HEK) 293 cells transfected with either pAd/MERS-
S or pAd control using Lipofectamine 2000 (Invitrogen) as described
previously [12]. Briefly, after 36 h at 37°C, the transfected cells were
harvested, trypsinized by incubation with 0.25% Trypsin, 2.21mMPlease cite this article as: E. Kim et al., Microneedle array delivere
translational development, EBioMedicine (2020), https://doi.org/10.1016EDTA, for 2-3 min at 37°C, followed by trypsin inactivation by adding 5
volumes of 10% FBS media, then washed with phosphate buffered
saline (PBS), and incubatedwith the mouse antiserum from each group
followed by staining with a PE-conjugated anti-mouse secondary IgG
antibody (Jackson Immuno Research). Data acquisition and analysis
were performed using LSRII (BD) and FlowJo (Tree Star) software.
2.7. ELISA
Sera from the animals were collected every two weeks and tested
for MERS-S1 protein-specific IgG by conventional ELISA as previously
described [12]. For long-lasting immunity, sera from the animals were
collected at week 23 and week 55 after primary inoculation and tested
for MERS-S1 protein-specific IgG by ELISA. Briefly, 96-well plates were
coated with the serum-free media from A549 cells infected with 10
MOI of Ad5.MERS-S1 for 48 h overnight at 4°C in carbonating buffer
(pH 9.5) and then blocked with PBS containing 0.05% Tween 20 (PBS-
T) and 2% bovine serum albumin (BSA) for 1 hr. Mouse sera were
diluted 1:200 in PBS-T with 1% BSA and incubated for two hours. After
the plates were washed, anti-mouse IgG-horseradish peroxidase
(HRP) (1:2000, SantaCruz) were added to each well and incubated for
one hour. The plates were washed three times and developed with
3,3’5,5’-tetramethylbenzidine, and the reaction was stopped with 1M
H2SO4 and absorbance at 450 nm was determined using an ELISA
reader (PerkinElmer 2030). For the binding of the recombinant pro-
teins and mouse sera against Ad5.MERS-S1, the 96-well plates were
coated with 200 ng of the purified recombinant proteins per well over-
night at 4°C in carbonate coating buffer (pH 9.5), followed by addition
of diluted pre-immunized sera and sera from the mouse infected with
AdC5 or Ad5.MERS-S1 [12], and carried out sequentially based on a
protocol similar to that described above. For ELISA of SARS-CoV-2-S1
antibody, the 96-well plates were coated with 200 ng of the purified
rSARS-CoV-2-S1 per well overnight at 4°C in carbonate coating buffer
(pH 9.5), followed by addition of 1:100 diluted mouse sera, and carried
out sequentially based on a protocol similar to that described above.
2.8. MERS-CoV neutralization assay
We tested the MERS-CoV neutralization activity of sera derived
from mice immunized with rMERS-S1f only, rMERS-S1fRS09, rMERS-
S1ffliC, MERS-S1f with MPLA, MNA-MERS-S1f, MNA-MERS-S1fRS09,
MNA-MERS-S1ffliC. Ad5.MERS-S1, and PBS as previously described
[12]. Mouse sera were obtained from the retro-orbital plexus every
two weeks for six weeks and tested for their ability to neutralize
MERS-CoV (EMC isolate). Briefly, virus (200 PFU) was premixed 1:1
with serial dilutions of sera from animal groups prior to inoculation
onto Vero cells, and viral infection was monitored by the occurrence
of a cytopathic effect at 72 h post-infection. Virus neutralization titers
(VNTs) were determined as the highest serum dilutions that showed
full protection against the cytopathic effect of MERS-CoV.
2.9. Statistical analysis
Statistical analyses were performed using GraphPad Prism (San
Diego, CA). Data were analyzed by one-way ANOVA, followed by Tukey's
post-hoc testing. Differences were considered significant if p< 0.05.
3. Results
3.1. Construction and characterization of recombinant proteins
To construct the recombinant trimeric MERS-S1 proteins, codon-
optimized MERS-S1 was fused to the T4 fibritin foldon trimerization
domain. Two additional variants were engineered by integrating the
TLR4 agonist peptide (RS09) or Salmonella typhimurium flagellin C
(fliC) fragment at the C-terminal of the foldon. Moreover, all threed recombinant coronavirus vaccines: Immunogenicity and rapid
/j.ebiom.2020.102743
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Virus (TEV) protease cleavage sequence at the carboxy terminus to
allow for metal chelating affinity purification and to facilitate down-
stream large-scale, purification compatible with clinical manufactur-
ing (Fig. 1A). A shuttle vector (pAd/MERS-S1f) was generated and a
replication-defective adenovirus 5, designated as Ad5.MERS-S1f, was
produced by loxP homologous recombination to use as a positive
control. To determine whether MERS-S1f, MERS-S1fRS09, and MERS-
S1ffliC would form trimeric structures, the serum-free supernatants
from A549 cells infected with each adenovirus were characterized by
SDS-PAGE and Western blot analysis. Three recombinant proteins
designed with a 6-histidine tag at the carboxy-terminal ends were
recognized by a monoclonal anti-6His antibody at the expected gly-
cosylated monomer molecular weights of about 130 kDa, 135 kDa,
and 200 kDa under the denaturing reduced (with b-ME) conditions.
The higher molecular-weight bands (dimers or trimers) were evident
under the denatured non-reduced (without b-ME) condition, and
were 2 or 3 times that of the reduced proteins (monomer), as
expected (Fig. 1B). [45,46] After being boiled in the sample buffer, the
proteins still migrated to the position of the trimer, indicating the
remarkable stability of these proteins. These results demonstrate that
recombinant MERS-S1 formed a trimeric conformation in the pres-
ence of the Fd trimerization motif. In addition, to delete the six-histi-
dine tag, the purified recombinant proteins were treated with AcTEV
protease (Life Technology) followed by affinity chromatography on a
nickel chelating resin to remove the six-histidine tags and poly-histi-
dine tagged protease from the cleavage reaction. The cleaved native
recombinant proteins were collected from the flow-through fraction
and used as coating antigens followed by detection with mouse
serum. Three purified recombinant proteins were detected using
serum from mice immunized with Ad5.MERS-S1 (p<0.05, one-way
ANOVA, followed by Tukey's post-hoc testing) prepared in our labo-
ratory previously [12], while no specific antibody binding activity
was detected in the serum of pre-immunized naïve mice or from con-
trol mice inoculated with AdC5 (Fig. 1C). ELISA data revealed that the
three recombinant MERS-S1 proteins had strong reactivity with
MERS-S1-specific antibodies.
3.2. Detection of membrane-bound MERS-S-specific antibodies
We next determined whether these recombinant subunit vaccines
could elicit antigen-specific immune responses in vivo. BALB/c mice
were inoculated subcutaneously with 25 mg of MERS-S1f, 25 mg of
MERS-S1fRS09, 40 mg of MERS-S1ffliC, or 25 mg of MERS-S1f plus 20
mg of the MPLA adjuvant to deliver the same molar ratio of immuno-
gen, or PBS as a negative control on day 0. The experimental schedule
is shown in Fig. 2A. Two weeks after immunization, we obtained sera
and examined binding to membrane-bound MERS-S by measuring
the reactivity against 293 cells transfected with pAd/MERS-S or pAd
using flow cytometry. As shown in Fig. 2B, in the presence of MPLA
adjuvant, rMERS-S1f induced a strong membrane-bound MERS-S-
specific IgG antibody response (p<0.05, one-way ANOVA, followed
by Tukey's post-hoc testing), while no significant antibody response
was detectable in the mouse sera of rMERS-S1f, rMERS-S1fRS09, and
rMERS-S1ffliC, when compared with PBS-immunized mouse sera. On
the other hand, in the absence of the adjuvant sequence, MNA intra-
cutaneous delivery of MERS-S1f, MERS-S1fRS09, or MERS-S1ffliC, at
the same molar ratio, elicited potent IgG antibody responses (p<0.05,
one-way ANOVA, followed by Tukey's post-hoc testing) that were
significantly stronger than those seen in s.c. immunized mice with
MPLA adjuvant (p<0.05, one-way ANOVA, followed by Tukey's post-
hoc testing), indicating the potential of MNAs as an effective recombi-
nant coronavirus vaccine delivery platform. (Fig. 2B). Mice immu-
nized with Ad5.MERS-S1 as a positive control developed significantly
higher levels of IgG antibody against cell membrane-bound MERS-S
as compared to negligible IgG levels in control mice inoculated withPlease cite this article as: E. Kim et al., Microneedle array delivere
translational development, EBioMedicine (2020), https://doi.org/10.1016PBS. Antibodies were not detected bound to cells transfected with
pAd without the immunogen insert (data not shown). These data
indicate that MERS-S1f protein with MPLA adjuvant and MNA deliv-
ered rMERS-S1f, rMERS-S1fRS09, and rMERS-S1ffliC induced strong
antibody response to membrane-bound MERS-S two weeks after a
single immunization.
3.3. Induction of humoral immune response to MERS-S1
To investigate the immunogenicity of trimeric MERS-S1f proteins,
at two and four weeks after a boosting immunization, sera were
obtained from all mice and screened for MERS-S1 specific antibodies
by ELISA. As shown in Fig. 3A, following s.c. vaccination only Ad5.
MERS-S1 elicited a MERS-S1-specific IgG antibody response (p<0.05,
one-way ANOVA, followed by Tukey's post-hoc testing) at week 2,
while no antibody response was detectable in the mouse sera of
rMERS-S1f, rMERS-S1fRS09, and rMERS-S1ffliC vaccinated mice when
compared with PBS-immunized mouse sera. However, 2 weeks after
boosting, antigen-specific IgG was detected in the sera of all s.c. immu-
nized mice, although the antibody titers were generally low. As an
exception to this, s.c. delivered MERS-S1fRS09 induced a relatively
strong MERS-S1-specific IgG antibody response (p<0.05, one-way
ANOVA, followed by Tukey's post-hoc testing, at weeks 4 and 6).
Importantly, mice immunized with each of the vaccine variants by
MNA delivery demonstrated significantly higher levels of antigen-spe-
cific IgG (p< 0.05, one-way ANOVA, followed by Tukey's post-hoc test-
ing) as compared to mice immunized with PBS, and there was with no
significant differences between the MNA vaccine variants (Fig. 3B).
To further demonstrate the immunogenicity of MERS-CoV subunit
vaccines, mouse sera were also tested for their ability to neutralize
MERS-CoV (EMC isolate). As shown in Fig. 3C, there were no detectable
MERS-CoV-neutralizing antibodies in the sera of mice immunized s.c.
with MERS-S1f-, MERS-S1fRS09-, or MERS-S1ffliC at week 4. However,
at week 6, sera of animals immunized with rMERS-S1fRS09, rMERS-
S1ffliC, or rMERS-S1f + MPLA had significant and comparable levels of
virus neutralizing activity, with geometric mean neutralizing titers of
104, 50.8, and 168, respectively. These titers were 5.4, 2.6, and 8.8 fold
higher than that of sera from the mice immunized with MERS-S1f only
(VNT mean, 19.2). Most importantly, as shown in Fig. 3D, at week 6 all
groups of MNA immunized mice developed significant levels of neu-
tralizing antibodies (p< 0.05, one-way ANOVA, followed by Tukey's
post-hoc testing). Animals immunized with MNA-rMERS-S1fRS09,
MNA-rMERS-S1ffliC, and Ad5.MERS-S1 had geometric mean neutraliz-
ing titers of 960, 832, and 3328, respectively. As expected, no neutral-
izing activity was detected in the sera of mice immunized with PBS.
These results suggest that MNA delivery of these candidate subunit
vaccines generates strong antibody-mediated neutralizing activity that
approaches that induced by live adenovector immunization and
exceeds that observed by s.c. delivery, even when a potent exogenous
adjuvant is added to the s.c. vaccine. The promising immunogenicity
of MNA MERS-CoV vaccines without chemical adjuvants makes them
an ideal candidate for future clinical studies.
3.4. Longevity of the immune response in mice vaccinated with subunit
vaccines
To evaluate the persistence of MERS-S1-specific immunity, mouse
sera was collected at weeks 23 and 55 after immunization and evalu-
ated for the presence of MERS-S1-specific IgG by ELISA. All animal
groups immunized s.c. with recombinant subunit vaccine demon-
strated the same or more levels of MERS-S1 IgG specific antibodies at
the later time points as those observed at week 6. Surprisingly, mice
immunized s.c. with rMERS-S1fRS09 had significantly higher levels of
IgG (p< 0.05, one-way ANOVA, followed by Tukey's post-hoc testing)
at week 23 compared with those observed at week 6 (Fig. 4A), and
this was sustained through 55 weeks. Importantly, MNA deliveredd recombinant coronavirus vaccines: Immunogenicity and rapid
/j.ebiom.2020.102743
Fig. 1. Construction of recombinant MERS-S1 Foldon subunit vaccines. (A) Schematic diagram of rMERS-S1s. The positions of the RBD (small dots) and transmembrane domain (stripes)
are indicated and S is divided into two subdomains, S1 and S2, at position 751. The vector was used to generate recombinant replication-deficient adenoviruses by homologous recom-
bination with the adenoviral genomic DNA. Arrows showed the cleavage site by TEV protease. Abbreviations are as follows: ITR, inverted terminal repeat; RBD, receptor binding
domain;F, T4 fibritin foldon trimerization domain; Tp, Tobacco Etch Virus (TEV) protease; fliC; Salmonella typhimurium flagellin C (B) Western blot of the supernatant of A549 cells
infected (10MOI) withmock (lane 1 and 5), Ad5.MERS-S1f (lane 2 and 6), Ad5.MERS-S1fRS09 (lane 3 and 7), or Ad5.MERS-S1ffliC (lane 4 and 8), respectively, with anti-6His monoclonal
antibody. The supernatants were resolved on SDS-4~20% polyacrylamide gel after being boiled in 2% SDS sample buffer with or without b-ME. (C) Detection of purified rMERS-S1fs with
mouse sera against Ad5.MERS-S1. The recombinant MERS-S1f proteins were purified using His60 Ni Superflow Resin under native conditions. After cleavage of the fusion protein by
TEV protease, 6xHis tag and protease were removed from the cleavage reaction by affinity chromatography on a nickel chelating resin. Three rMERS-S1fs were coated in 96-well plate
with 200ng/well ELISA and detected with mouse sera against Ad5.MERS-S1. Significance was determined by one-way ANOVA followed by Tukey’s test. *p< 0.05.
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Fig. 2. MNA delivered subunit vaccines elicit antibodies recognizing cell surface bound MERS-S proteins. (A) The experimental schedule representing the timeline for the
immunizations. (B) Flow cytometry assay of 293 cells expressing MERS-S at the cell surface. HEK 293 cells were transfected with pAd/MERS-S (gray bar) or control pAd (white bar).
At 36 h post-transfection, binding to MERS-S at the cell surface was analyzed by incubation with mice sera obtained at week 2 after immunization followed by staining with PE-con-
jugated anti-mouse IgG. St Significance was determined by one-way ANOVA followed by Tukey’s test. *p < 0.05.
ARTICLE IN PRESS
JID: EBIOM [m5G;April 1, 2020;16:51]
E. Kim et al. / EBioMedicine 00 (2020) 102743 7vaccines demonstrated generally increasing (statistically significant)
levels of MERS-S1-specific antibody through the 23- and 55-week
time points (Fig. 4B). No significant difference was observed in the
mice immunized with PBS or Ad5.MERS-S1 at any time point evalu-
ated. These results indicate that MNA-delivered subunit vaccines
induce potent and long-lasting MERS-S1 specific antibody responses
and MNA delivery is a viable approach for the clinical development
of subunit vaccines against emerging infectious diseases such as
COVID-19.3.5. Immunogenicity of MNA delivered SARS-CoV-2-S1 subunit vaccines
Based on these MERS-S1 vaccine results and the urgency of the
public health threat by COVID-19, we focused our efforts on the
development of SARS-CoV-2-S1 and SARS-CoV-2-S1fRS09 subunit
vaccines (shown in Fig. 5A). The size and trimerization product of the
vaccine was confirmed by western blot (Fig. 5B). The aggregation in
Fig. 5B could be attributed to the trimerization of the S1’s segments
NTD, CTD1, and CDT2 domains or the ability of the histidine tag to oli-
gomerize the tagged proteins [4749]. We used MNAs to vaccinate
mice with SARS-CoV-2-S1 and SARS-CoV-2-S1fRS09 subunit vac-
cines. Sera was collected prior to immunization (week 0) and at
weeks 1 2, 3, and 4, and evaluated for the presence of SARS-CoV-2-S1Please cite this article as: E. Kim et al., Microneedle array delivere
translational development, EBioMedicine (2020), https://doi.org/10.1016specific antibodies by ELISA as previously described. As shown in
Fig. 5C, significantly high (p< 0.05, one-way ANOVA, followed by
Tukey's post-hoc testing) SARS-CoV-2 IgG responses were detected
as early as week 2 for all subunit vaccines as compared to control
groups. The inclusion of the RS09 ligand in the trimer subunit
resulted in a negligible effect on SARS-CoV-2 specific IgG titers. Fur-
ther, in our preliminary study, the immunogenicity of gamma irradia-
tion sterilized MNA vaccines was comparable to that of unirradiated
MNA vaccines (Data not shown), thereby supporting the feasibility of
gamma irradiation as a terminal sterilization approach for our clinical
MNA-SARS-CoV-2 subunit vaccines.3.6. Rapid development of clinically applicable MNA SARS-CoV-2 S1
subunit vaccines
Relying on our experience with MERS-CoV and SARS-CoV
vaccines, and our experience with clinical production and human
applications of MNAs, we developed standard operating procedures
(SOPs) for the rapid development of clinic grade MNA SARS-CoV-2
subunit vaccines. Our production strategy and the related timeline is
outlined in Table 1. First, we designed, optimized, and cloned the S1
subunits beginning when the sequence became publicly available.
Subsequently, we produced S1 subunit proteins, purified them, andd recombinant coronavirus vaccines: Immunogenicity and rapid
/j.ebiom.2020.102743
Fig. 3. Induction of humoral immune response in mice vaccinated with recombinant MERS-S1 vaccines. BALB/c mice were immunized subcutaneously or intracutaneously
with 20 mg of each rMERS-S1 subunit vaccines s.c., with or without 20 mg of MPLA, or by MNA delivery of the same subunit proteins, or with 1011vp of Ad5.MERS-S1 as a positive
control. On day 14 mice were boosted using the same regimen as the prime immunization. On weeks 0, 2, 4, and 6 after treatment, immune sera from mice were collected, diluted
(200x), and tested for the presence of MERS-S1-specific antibodies by ELISA (A and B) or by MERS-CoV-neutralization assay without dilution (C and D). MERS-CoV virus-neutralizing
titers (VNTs) were measured every week after primary immunization using Vero cells by determining the highest dilution inhibiting MERS-CoV infection by 100%. Significance was
determined by one-way ANOVA followed by Tukey’s test. *p < 0.05.White and black circles in Fig. 3C and D represent week 4 and week 6, respectively.
Fig. 4. Longevity of immune response in mice vaccinated with subunit vaccines. BALB/c mice were immunized with subunit vaccines as described in the Fig. 3 legend. On week
23 and 55 after immunization sera were collected, diluted (200x) in PBS, and tested for the presence of MERS-S1-specific antibodies by ELISA. Significance was determined by one-
way ANOVA followed by Tukey’s test. *p < 0.05.
ARTICLE IN PRESS
JID: EBIOM [m5G;April 1, 2020;16:51]
Please cite this article as: E. Kim et al., Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid
translational development, EBioMedicine (2020), https://doi.org/10.1016/j.ebiom.2020.102743
8 E. Kim et al. / EBioMedicine 00 (2020) 102743
Fig. 5. Induction of humoral immune response in mice immunized with MNA delivered SARS-CoV-2-S1 vaccines. (A) Schematic diagram of rSARS-CoV-2-S1s. The positions of the
RBD (small dots) and transmembrane domain (stripes) are indicated and S is divided into two subdomains, S1 and S2, at position 681. The SARS-CoV-2-S1 or SARS-CoV-2-S1fRS09
gene was inserted into pmax Cloning expression vector. (B) Western blot of the purified rSARS-CoV-2-S1 (lane 1 and 3) or rSARS-CoV-2-S1fRS09 (lane 2 and 4) proteins with anti-6His
monoclonal antibody. The purified proteins were resolved on 10% Tris/Glycine gel after being boiled in 2% SDS sample buffer with b-ME or in native sample buffer without b-ME. (C)
C57BL/6 mice were immunized intradermally with MNAs containing 20 mg of rSARS-CoV-2-S1 or rSARS-CoV-2-S1fRS09. Immune sera from mice were collected every week, diluted
(100x) in PBS, and tested for the presence of SARS-CoV-2-S1-specific antibodies by ELISA. Significance was determined by one-way ANOVA followed by Tukey’s test. *p< 0.05.
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pre-clinical testing in the animal model. Next, we vaccinated mice
with MNA-rSARS-CoV-2 vaccines and began analysis of antibody
responses induced in immunized animals. These preclinical studiesPlease cite this article as: E. Kim et al., Microneedle array delivere
translational development, EBioMedicine (2020), https://doi.org/10.1016were initiated within 4 weeks of the SARS-CoV-2 spike sequence
becoming publicly available. In parallel, to enable future regulatory
approval and rapid clinical testing, we employed Good Manufactur-
ing Processes (GMP) using a certified master cell bank (MCB) to scaled recombinant coronavirus vaccines: Immunogenicity and rapid
/j.ebiom.2020.102743
Table 1
Timeline for the development of SARS-CoV-2 subunit vaccines.
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porated the subunits into dissolvable MNAs or syringes using pro-
cesses developed through our clinical production and quality control
of MNAs (ClinicalTrials.gov Identifier: NCT02192021). This was fol-
lowed by (1) gamma irradiation to assure sterilization of the vaccine
loaded MNAs and syringes that will be used as control groups in our
clinical trials, and (2) analysis of established release criteria, the latter
of which is now ongoing and will be used for an application for IND
approval that will enable a safety focused phase I clinical trial.
4. Discussion
Here, we present the rapid design and translational development of
MNA SARS-CoV-2 vaccines capable of generating potent antigen-specific
antibody responses by capitalizing on our substantial experience with
Coronavirus vaccines andMNA delivery platforms.
First, we describe the design and production of trimeric recombinant
subunit vaccines against MERS-CoV-S1 with and without integrated
immunostimulatory TLR ligand sequences. We tested the immunoge-
nicity of these vaccine variants delivered either by traditional subcuta-
neous needle injection or using MNAs to more specifically target
vaccine components to the immune fertile skin microenvironment. We
found that MNA delivery of MERS-CoV-S1 vaccines induced stronger
humoral responses than traditional needle injections regardless of the
inclusion of TLR ligand binding sequences (Fig. 3A,B). On the other
hand, integration of the RS09 TLR4 binding sequence in the subunit tri-
mer resulted in relatively stronger antibody responses than those with-
out RS09 when vaccines were delivered by subcutaneous injection
(Fig. 3A). Interestingly, the inclusion of the flagellin TLR5 binding
sequence had no effect on the immunogenicity of the s.c. delivered vac-
cines (Fig. 3B). Importantly, significant neutralizing activity was
observed in vaccinated animals at week 6. Consistent with previous IgG
results, the presence of RS09 in the subunit trimer improved the neu-
tralization function of antibodies from s.c. immunized mice, and this
was the only immunogen that resulted in significant neutralization.
Notably, MNA delivery was more effective in eliciting neutralizing anti-
bodies for all vaccines. All MNA vaccines generated higher levels of neu-
tralizing antibody, even beyond those induced by an s.c. delivered
MPLA adjuvanted vaccine, and similar to those seen following the deliv-
ery of the rMERS-S1f construct via recombinant adenoviral vector.
Though levels of neutralizing antibody were elevated in mice immu-
nized with trimers including either RS09 or flagellin, these increases
were not statistically significant when compared to the MNA vaccinePlease cite this article as: E. Kim et al., Microneedle array delivere
translational development, EBioMedicine (2020), https://doi.org/10.1016alone (Fig. 3C,D). Thus, though the contributions of the integrated TLR
ligands to the strong immune responses induced by MNA vaccines
appear to be minimal, they provide promising benefit for s.c. vaccine
administration, and their potential for contribution to immunogenicity
in humans has yet to be determined. Importantly, we and others have
shown effective protection against MERS-CoV challenge in hDPP4-
expressing mice at comparable or lower neutralizing titers in previous
passive immunotherapy studies with MERS-CoV-specific antibodies or
neutralizing sera obtained fromMERS-CoV immune humans or animals
[5053]. Furthermore, we have previously demonstrated that antibod-
ies directed against S1 domain of the spike protein, as detected in our
study by ELISA, exert neutralizing activity against live coronaviruses
[54].
Based on our results with MERS-CoV-S1 vaccines, we focused our
efforts to develop MNA SARS-CoV-2 vaccines. Using the described
approach, within three weeks of publication of the SARS-CoV-2- spike
glycoprotein sequence, we produced both rSARS-CoV-S1 and rSARS-
CoV-S1fRS09 immunogens and fabricated dissolvable MNAs incorporat-
ing these vaccines in quantities sufficient for pre-clinical testing. MNA
delivery of either rSARS-CoV-2-S1 or rSARS-CoV-2-S1fRS09 induced
substantial and statistically significant increases in antigen-specific anti-
bodies responses as soon as week 2 compared to pre-immunization and
week 1 responses. The inclusion of RS09 did not have a significant effect
on antibody titer at the 2, 3, or 4-week time points. Furthermore, the
immunogenicity of MNA vaccines was maintained after gamma irradia-
tion sterilization, suggesting a viable method to assure sterility of our
MNA vaccines for clinical applications. The significant antibody titers
we observed at the early time points before boosting strongly supports
the feasibility of our MNA-SARS-CoV-2 vaccines, particularly in the
context of similar results obtained with the analogous MERS-CoV-S1
constructs under the same conditions.
Neutralization assays are important to ensure antibody function;
however, at this early timepoint, we do not have access to validated
assays for neutralizing antibodies against SARS-CoV-2. Further, at the
time of submission of this manuscript, we are just over four weeks
post-immunization and based on our MERS-CoV studies, the reliable
detection of neutralizing SARS-CoV-2 antibodies may require at least
six weeks post immunization. We speculate that this delay in the
neutralizing response is likely a result of the time needed for affinity
maturation of the SARS-CoV-2 neutralizing IgG antibodies. However,
we believe that MNA-SARS-CoV-2 vaccines will very likely induce
neutralizing immunity as suggested by the vigorous early antibody
responses, and commonalities between both the vaccines and thed recombinant coronavirus vaccines: Immunogenicity and rapid
/j.ebiom.2020.102743
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humans immunized with these vaccine candidates will have similar
responses and be protected from SARS-CoV-2 or MERS-CoV infec-
tions, our studies demonstrate that development, production, and
initial animal testing of clinically translatable MNA vaccine candi-
dates against SARS-CoV-2 and other emerging infections can be rap-
idly accomplished. Studies directly assessing important correlates of
human efficacy would provide additional support for efficacy in
humans. In this regard it will be important to determine whether
antibodies from MNA-SARS-CoV-2 immunized animals will neutral-
ize virus infectivity. Further, the demonstration of protection from
infection in animal challenge models, such as the hACE2 transgenic
mouse model, would be informative. We plan to do these studies
when these models are developed and validated. Finally, we note
that the immunogenicity differences between MNA coronavirus vac-
cines and coronavirus vaccines delivered by traditional needle injec-
tion that we observe will need to be evaluated in clinical trials to
establish the clinical advantages of MNA delivery.
Microneedle array mediated immunization has several mechanistic
differences from traditional intramuscular or subcutaneous needle
injections, which could explain the variations in the magnitude and
kinetics of the ensuing responses [5559]. The skin is immunologically
reactive and contains a high density of antigen presenting and
immune-accessory cells with innate immune function including kera-
tinocytes, mast cells, and innate lymphocytes [25,6062]. Redundant
skin immunoregulatory circuits can respond to a wide variety of dam-
age or infection related signals to rapidly orchestrate an innate
immune response [6264]. Further, MNAs deliver vaccine compo-
nents to a defined 3D space within the skin microenvironment which
results in very high vaccine concentrations with relatively low dose
antigen delivery. MNA delivery of antigens to targeted skin microen-
vironments results in prolonged exposure of skin resident antigen pre-
senting cells and other innate immune cells to the skin delivered
components [65]. Moreover, transient mechanical stress from micro-
needle insertion can induce a natural local innate immune response
which can serve as a physical adjuvant to enhance antigen-specific
adaptive immunity [57]. MNA delivery of lower doses to a localized 3D
space improves safety by reducing systemic exposure [27]. Further,
MNA delivery has the potential to accelerate the process of vaccine
production and to significantly reduce cost by considerably reducing
the required vaccine doses [58]. The stability studies with our MNA
SARS-CoV-2 vaccines are currently in progress, however; there is evi-
dence in the literature that vaccine components including proteins are
typically stabilized by integration into the MNA polymer matrix, and
retain their conformational structures, as evidenced by maintenance
of antibody binding function [29,66] or retained immunogenicity of
recombinant adenovirus vaccines for at least a month at 25 °C [67].
Thus, MNA vaccines offer the potential to eliminate the substantial
costs associated with the “cold chain” necessary for current vaccines
[34,68]. Finally, the MNAs described here are designed to be applied
without the need for an applicator or any specialized equipment,
supporting the potential for self-administration. As such, these
features provide several important advantages that support the future
development of MNA vaccines for global protection from rapidly
emerging infectious diseases.
Taken together, our studies demonstrate the speed at which vac-
cines against emerging infections can be designed and produced using
the recent advances in recombinant DNA technology. Combining
emerging biotechnology methods with bioengineering advances in
vaccine delivery strategies, it may now be possible to rapidly produce
clinically-translatable vaccines against novel pathogens for human
testing and subsequent global distribution in time to significantly
impact the spread of disease.Please cite this article as: E. Kim et al., Microneedle array delivere
translational development, EBioMedicine (2020), https://doi.org/10.1016Acknowledgments
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